Evidence map›Paper›PMID 30174398›Full record

ArticleAnnals of gastroenterology

Presepsin levels in cirrhotic patients with bacterial infections and/or portal hypertension-related bleeding, presenting with or without acute kidney injury.

Ioannis Elefsiniotis, Stefanos A Tsakiris, Georgia Barla, Athanasia Tasovasili, Dimitrios Vrachatis, Christos Mavrogiannis

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Evaluation of presepsin dynamics in septic patients with and without liver cirrhosis.Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures) · 2026
    Article
  2. Article
  3. Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis.International journal of molecular sciences · 2024
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Ioannis ElefsiniotisAcademic Department of Internal Medicine, Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens, Greece, The study was partially supported by an unrestricted research grant from AbbVie Pharmaceuticals S.A. The authors state that AbbVie Pharmaceuticals S.A. had no involvement in the study design, collection, analysis, interpretation of data, writing of the report or the decision to submit the manuscript for publication.
Stefanos A TsakirisAcademic Department of Internal Medicine, Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens, Greece, The study was partially supported by an unrestricted research grant from AbbVie Pharmaceuticals S.A. The authors state that AbbVie Pharmaceuticals S.A. had no involvement in the study design, collection, analysis, interpretation of data, writing of the report or the decision to submit the manuscript for publication.
Georgia BarlaAcademic Department of Internal Medicine, Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens, Greece, The study was partially supported by an unrestricted research grant from AbbVie Pharmaceuticals S.A. The authors state that AbbVie Pharmaceuticals S.A. had no involvement in the study design, collection, analysis, interpretation of data, writing of the report or the decision to submit the manuscript for publication.
Athanasia TasovasiliAcademic Department of Internal Medicine, Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens, Greece, The study was partially supported by an unrestricted research grant from AbbVie Pharmaceuticals S.A. The authors state that AbbVie Pharmaceuticals S.A. had no involvement in the study design, collection, analysis, interpretation of data, writing of the report or the decision to submit the manuscript for publication.
Dimitrios VrachatisAcademic Department of Internal Medicine, Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens, Greece, The study was partially supported by an unrestricted research grant from AbbVie Pharmaceuticals S.A. The authors state that AbbVie Pharmaceuticals S.A. had no involvement in the study design, collection, analysis, interpretation of data, writing of the report or the decision to submit the manuscript for publication.
Christos MavrogiannisAcademic Department of Internal Medicine, Hepatogastroenterology Unit, "Agioi Anargyroi" General and Oncology Hospital of Kifisia, National and Kapodistrian University of Athens, Greece, The study was partially supported by an unrestricted research grant from AbbVie Pharmaceuticals S.A. The authors state that AbbVie Pharmaceuticals S.A. had no involvement in the study design, collection, analysis, interpretation of data, writing of the report or the decision to submit the manuscript for publication.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBacterial infections in cirrhotic patients remain a challenge. Presepsin has been proposed as a valuable sepsis biomarker. We aimed to assess plasma presepsin levels in uncomplicated cirrhotic patients and to correlate them with liver disease severity and complicating events, defined as documented bacterial infection with or without concomitant portal hypertension-related bleeding, or bleeding without documented bacterial infection, with or without acute kidney injury.

methodsWe prospectively evaluated the presepsin levels of 108 consecutive uncomplicated cirrhotic patients with compensated (55, 50.9%) or decompensated (53, 49.1%) cirrhosis. During the follow up, 20 patients were reevaluated for a complicating event.

resultsMean baseline presepsin levels of the entire population were 440.4 pg/mL. Patients with decompensated cirrhosis exhibited significantly higher baseline levels than patients with compensated cirrhosis (599.1±492.2 vs. 287.5±130.5 pg/mL, P<0.001). In complicated cirrhotic patients, admission levels were remarkably higher than baseline (1438.0±1247.2 vs. 725.3±602.8 pg/mL, P<0.001), especially in those who developed acute kidney injury compared to those who did not (1827.3±1118.8 vs. 1048.7±1302.1 pg/mL, P<0.05). Baseline presepsin levels, using a cutoff of 607.5 pg/mL, could predict liver disease-related 3-month mortality with 77.8% sensitivity and 86.9% specificity: area under the receiver operating characteristic curve 0.825; 95% confidence interval 0.684-0.967; P<0.01.

conclusionsPlasma presepsin levels are elevated in uncomplicated cirrhotic patients, especially in those with advanced liver disease, and rise further in those complicated by an event. Baseline presepsin levels in cirrhotic patients could be used as an additional marker, along with the model for end-stage liver disease score, to predict short-term outcomes.

Indexed as

bacterial infectionsliver cirrhosismodel for end-stage liver disease scorePresepsin

Identifiers

PMID30174398
PMCPMC6102455
OpenAlexW2884634998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.